ACT Biotech's Telatinib Demonstrates Significant Progress in Stomach Cancer Treatment; Phase 2 Data to be Presented at American Society of Clinical Oncology
6/2/2011 10:14:49 AM
SAN FRANCISCO, June 2, 2011 (GLOBE NEWSWIRE) -- ACT Biotech, Inc., a biopharmaceutical company focused on the development of highly targeted, oral therapeutics for the treatment of cancer, announced positive data from the Phase 2 clinical trial evaluating the novel oral antiangiogenic agent telatinib in combination with standard-of-care chemotherapy regimen as first-line treatment for patients with metastatic stomach cancer, the second most deadly tumor type in the world. The trial was conducted in multiple centers in the U.S. and Spain. These data will be presented at the eighth annual American Society of Clinical Oncology annual meeting that will take place June 3-6, 2011, in Chicago, IL.
comments powered by